Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Myelodysplastic syndromes
ADR ID BADD_A02927
ADR Hierarchy
01      Blood and lymphatic system disorders
01.10      Leukaemias
01.10.04      Myelodysplastic syndromes
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.01      Leukaemias
16.01.04      Myelodysplastic syndromes
Description Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. [MeSH]
MedDRA Code 10028536
MeSH ID D009190
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Myelodysplastic Syndromes | Myelodysplastic Syndrome | Syndrome, Myelodysplastic | Syndromes, Myelodysplastic | Dysmyelopoietic Syndromes | Dysmyelopoietic Syndrome | Syndrome, Dysmyelopoietic | Syndromes, Dysmyelopoietic | Hematopoetic Myelodysplasia | Hematopoetic Myelodysplasias | Myelodysplasia, Hematopoetic | Myelodysplasias, Hematopoetic
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02482Acalabrutinib0.000112%
BADD_D02485Talazoparib0.000336%
BADD_D02510Rucaparib0.000392%
BADD_D02531Avapritinib0.000112%
BADD_D02568Lutetium oxodotreotide lu-177-
The 4th Page    First    Pre   4    Total 4 Pages